the aid library

Rabies monoclonal antibodies post exposure prophylaxis

World Health Organization WHO (2016) C_WHO

Accessed Nov. 28,2016

Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a Wo

Driscoll, A.J.; Hasan Arshad, S.; Bont, L. et al. Vaccine (2020) CC

The article reviews the impact of respiratory syncytial virus (RSV) on global health, emphasizing its significant burden on infants, children, and the elderly. It discusses current and emerging prevention strategies, including the development and implementation of vaccines and ... more

COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine

World Health Organization WHO (2022) C_WHO

The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.

Schisto POC-CCA. Rapid test for qualitative detection of: Bilharzia (Schistosomiasis)

Rapid Diagnostics (2018) CC

25 Diagnostic Tests

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Greinacher, A., et al. (2021) CC

New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840

Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update

Lalloo, U.G.; Kalla, I.S.; Abdool-Gaffar, S. et al. African Journal of Thoracic and Critical Care Medicine (2021) CC

sthma prevalence is increasing worldwide, and surveys indicate that most patients in developed and developing countries, including South Africa, do not receive optimal care and are therefore not well controlled. Standard management guidelines adapted to in-country realities are important to support ... more

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

John R. Perfect, William E. Dismukes, Francoise Dromer, et al. Infectious Diseases Society of America (2010)

Clinical Infectious Diseases 2010; 50:291–322

Clinical guidelines for breast cancer control and managment

Ministry of Health, Republic of South Africa (2018) CC

WHO advisory committee on variola virus research: report of the twenty-third meeting, virtual meeting, 3-4 November 2021

World Health Organization (WHO) (2021) C_WHO

The Committee discussed the implications for preparedness for smallpox-like events reflected by the ongoing COVID-19 pandemic. The Committee noted how quickly diagnostics and vaccines could be developed and deployed when resources and political will were abundant. This rapidity was also due to the f ... more

NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine

World Health Organization WHO (2022) CC

9 Febr. 2022 The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below. Th ... more

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. fir ... more

Руководство по эпидемиологическому надзору за вариантами SARS-CoV-2

World Health Organisation (WHO) (2021) C_WHO

Временные рекомендации 9 августа 2021 г. Цель данного документа - описать минимальный набор мероприятий по эпиднадзору, рекомендуемых на национальном уровне для вы� ... more

COVID Reference 2021.6 EN
recommended

Kamps, B.S.; Camp, R. and C. Hoffmann (2021) CC

6th edition 13 January 2021 CR 2021.6.10, uploaded on 27 May 2021 Find eight editions: Deutsch | English | Español | Français | Italiano | Português | Tiếng Việt | Türkçe https://covidreference.com/download

COVID-19 Scientific and Public Health Policy Update – (6 July 2022)

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.

Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration

E. J. Abrams; J. Ananworanich; M. Archary; M.N. Ngongondo; P. Brouwers J Acquir Immune Defic Syndr; Pub Med (2018) C2

J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

The ACT-Accelerator: Two years of impact

World Health Organization WHO (2022) C_WHO

The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.